Optimizing ultra‑high dose‑rate (FLASH) radiation to spare healthy tissue
Preclinical optimization of ultra-high dose rate (FLASH) radiotherapy parameters for translational relevance
This project looks at ultra‑fast (FLASH) radiation methods that aim to control tumors while reducing damage to healthy organs for people with cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tx Md Anderson Can Ctr NIH-funded |
| Lab location | 1 site (Houston, United States) |
| Project ID | NIH-11166600 on NIH RePORTER |
What this research studies
Researchers at MD Anderson are testing different beam settings and fractionation schedules in lab and animal models to find when FLASH radiation protects normal tissues without losing tumor control. They will directly compare FLASH versus conventional dose‑rate radiation and use precise tumor cure assays (TCD50) rather than just measuring growth delay. The team will standardize physical beam parameters to explain why past studies sometimes disagreed about FLASH benefits. Results are intended to guide safer, more consistent clinical trials for patients.
Who could benefit from this research
Good fit: People with tumors commonly treated with radiation—such as brain, lung, or abdominal/GI cancers—would be the likely candidates for future FLASH clinical trials informed by this work.
Not a fit: Patients whose cancers are not treated with radiation or whose tumors cannot be targeted safely by radiation are unlikely to benefit directly.
Why it matters
Potential benefit: If successful, this work could enable radiation that controls cancer while causing fewer side effects to healthy organs.
How similar studies have performed: Preclinical studies have often shown promising normal‑tissue protection with FLASH but results have been mixed across organs and models, and clinical experience is still limited.
Where this research is happening
Houston, United States
- University of Tx Md Anderson Can Ctr — Houston, United States (Active)
Researchers
- Principal investigator: Schueler, Emil — University of Tx Md Anderson Can Ctr
- Study coordinator: Schueler, Emil
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.